Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Not Only Does Our Gut Have Brain Cells It Can Also Grow New Ones, Study
A new US study has added to existing knowledge about the million or so brain cells in our gut by using lab mice to show that it can also grow
generic viagra online
Kansas Gov. Parkinson Urged To Veto Removal Of Planned Parenthood Funding In Budget
Supporters of Planned Parenthood of Kansas and Mid-Missouri are urging Gov. Mark Parkinson (D) to veto a provision in a budget bill (H.B. 2373) that would eliminate the group"s funding, the AP/Wichita Eagle reports. The bill aims to balance Kansas" budget for the fiscal year that begins July 1. The original bill was approved by the Legislature and former Gov. Kathleen Sebelius, who resigned in April to become HHS secretary. It included $250,000 in state funding for Planned Parenthood for FY 2010. However, lawmakers later amended the budget with a new bill that includes a provision eliminating the funding after state revenue projections declined, the AP/Eagle reports.While antiabortion-rights advocates want Parkinson to retain the provision, about two dozen supporters of Planned Parenthood gathered on Tuesday to urge Parkinson to line-item veto the provision. They left petitions at the governor"s office with about 3,500 signatures, the AP/Eagle reports. Planned Parenthood attorney Pedro Irigonegarary said the loss of funding would negatively impact "a large number of innocent people." He added that the group "is about family values. They have taken those two words from us and now it"s time to take them back." According to the AP/Eagle, Planned Parenthood said the state funding is given to its Ellis and Sedgwick county clinics, which do not perform abortions. The group also noted that no state funds are used for abortion procedures performed at its clinics in Overland Park, a suburb of Kansas City.The governor"s office said that Parkinson intends to act on the bill sometime this week, although he will not announce what action he will take on any legislation in advance. Parkinson has said that he holds "very similar" views on abortion rights as Sebelius, who supports such rights. However, he has yet to act on any bills regarding abortion, the AP/Eagle reports. Mary Kay Culp, executive director of Kansans for Life, said that the group is asking members to contact legislators and the governor"s office in support of retaining the measure. The AP/Eagle reports that if Parkinson vetoes the measure, lawmakers could attempt to override it (Manning, AP/Wichita Eagle, 5/19).
News of the day
Baxter Advances To Full-Scale Production Of A/H1N1 Vaccine
Baxter International Inc. (NYSE: BAX) announced that it has completed testing and evaluation of the A/H1N1 influenza virus and is now in full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology. Baxter received an A/H1N1 strain from the U.S. Centers for Disease Control and Prevention [a World Health Organization (WHO) Collaborating Center] in early May and is diligently working to deliver a pandemic vaccine for use as early as July.
Diagnostics

Nanobiotix Reports Exciting Preclinical Results Using Its NanoXray™ Therapeutics Technology To Destroy Tumors

Nanobiotix, an emerging nanomedicine company, announced exciting preclinical results using its patented nanoXray therapeutics platform to fight tumors. The preclinical study, performed at Institut Gustave Roussy, one of Europe"s leading cancer treatment centers, showed that an intratumoral injection of NBTXR3 nanoparticles and activated via standard radiation therapy led to complete tumor regression in mice at 60 days, compared to zero tumor regression in mice treated with xray only or NBTXR3 only. The study was led by principal investigator, Jean Bourhis, M.D., Ph.D. a prominent radiation oncologist and researcher at Institut Gustave Roussy. Nanobiotix is using technology that it calls "nanoXray therapeutics" to resolve radiation therapy"s biggest drawback: destruction of healthy tissue and its subsequent deleterious side effects when a high dose of xray is necessary. The Company believes that nanoXray therapeutics offer a dramatic innovation in cancer therapy, based on a technology that is designed to allow destruction of cancer cells only-a new treatment weapon that could be used alone, or in concert with existing anticancer protocols: chemotherapy, surgery, and immunotherapy. Because NBTXR3 is comprised of crystalline nanoparticles, it does not have deleterious effects on healthy cells, unlike chemotherapy or other systemic anticancer agents. "Our nanotechnology is designed to allow for the precise destruction of cancer cells via the controlled application of an outside-the-body energy -in this case, an xray. We are extremely excited by these preclinical results, which demonstrate the novel therapeutic effect of nanoparticles on human tumor models," said Laurent Lçİvy, Ph.D., President and CEO of Nanobiotix and Co-President of the French Technology Platform on Nanotechnology (FTPN). "It is very important to note that after 120 days of this study, 90 percent of the mice treated with NBTXR3 nanoparticles activated by radiotherapy were still alive, whereas all of the mice in the other two groups had to be sacrificed after 60 days due to tumor progression," added Elsa Borghi, M.D., Chief Medical Officer for Nanobiotix. One in four deaths in the United States is from cancer, making it the second-leading cause of death after heart attack. Radiation therapy-also called radiotherapy, xray, or irradiation-is typically used to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated by damaging their genetic material, making it impossible for these cells to continue to grow and divide. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue. About half of all cancer patients receive some type of radiation therapy, which may be used alone or in combination with other cancer treatments, such as chemotherapy or surgery. Radiation therapy may be used to treat almost every type of solid tumor. About the NBTXR3 Preclinical Study Through experiments on resistant and radiosensitive tumor models, NBTXR3 activated by xray has shown its strong ability to reduce the clonogenic activity of cancer cells. In vivo models have demonstrated the same type of improvement, up to tumor elimination, when radiotherapy alone could show only five-day tumor growth delay. In several models including an HCT116 colon cancer tumor and an HT1080 fibrosarcoma tumor, NBTXR3 has strongly impaired tumor growth and improved Overall Survival (OS). The study showed a statistically significant tumor regression and a prolongation of survival in NBTXR3-treated mice when irradiated both with one dose of 8 Gy or two doses of 4 Gy. This is an important parameter since radiation therapy is delivered in fractions to cancer patients. Similar results were also obtained with Swiss nude mice bearing sarcoma tumors, in spite of the fact that these are known to be resistant to radiotherapy. Other studies in non-epithelial cancer models demonstrated comparable survival improvements as well. Compatibility with different energy s has also been demonstrated, proving that NBTXR3 could be easily used with the different radiotherapy equipment presently on the market. Nanobiotix


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

İ Copyright 2009